SCHEMBL6134696

SCHEMBL6134696

CCCCC1(OC)CCN(c2ccc(C(=O)NCC(=O)c3ccc(C(=O)OCC)cc3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.42
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
MAPT P10636 4/20 0.39
TSHR P16473 3/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
STAT3 P40763 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HDAC3 O15379 4/20 0.38
HDAC8 Q9BY41 4/20 0.38
CHRNA10 Q9GZZ6 1/20 0.38
CHRNA9 Q9UGM1 1/20 0.38
ATM Q13315 1/20 0.38
HTT P42858 2/20 0.37
HPGD P15428 2/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134196 0.89 HTT (0.46) KMT2AMEN1MAPTTSHRLMNA
SCHEMBL6134615 0.82 HDAC3 (0.48) KMT2AMEN1MAPTTSHRLMNA
SCHEMBL6134369 0.81 HDAC3 (0.46) KMT2AMAPTTSHRLMNAALDH1A1
SCHEMBL6134891 0.77 USP2 (0.46) MAPTTSHRALDH1A1MAPK1SMN1; SMN2
SCHEMBL6134072 0.76 SIRT2 (0.39) KMT2AMEN1MAPTLMNA
SCHEMBL6134410 0.73 ALDH1A1 (0.41) KMT2AMEN1MAPTTSHRLMNA
SCHEMBL1743458 0.71 HPGD (0.42) KMT2AMEN1ALDH1A1MAPK1RAB9A
SCHEMBL2941901 0.71 HTT (0.55) KMT2AMEN1MAPTTSHRLMNA
SCHEMBL2951762 0.71 HPGD (0.55) KMT2AMEN1MAPTTSHRLMNA
SCHEMBL20188098 0.70 HPGD (0.65) KMT2AMEN1MAPTTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004014-A1 Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-06 US disclosed
WO-2004113368-A1 CYCLIC LIPOPEPTIDES ASTELLAS PHARMA INC. (JP) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004014-A1 Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals MAN2B1, MAN2A1, MANBA CSNK1D 1928/4885KMT2A 4054/4885MEN1 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.